Published in Pediatr Pulmonol on September 01, 2010
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA (2012) 1.25
Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One (2011) 1.16
Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax (2012) 1.12
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol (2011) 1.10
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros (2012) 1.05
Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc (2014) 0.92
Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis. Pediatr Pulmonol (2012) 0.86
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr (2015) 0.84
Inhaled antibiotics in cystic fibrosis: what's new? J R Soc Med (2012) 0.82
LasR Variant Cystic Fibrosis Isolates Reveal an Adaptable Quorum-Sensing Hierarchy in Pseudomonas aeruginosa. MBio (2016) 0.81
Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. BMC Pulm Med (2015) 0.79
The Evolution of Cystic Fibrosis Care. Chest (2015) 0.78
Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. Ann Am Thorac Soc (2015) 0.76
Children with Chronic Lung Disease: Facilitating Smoking Cessation for their Caregivers. J Community Health (2015) 0.75
The Impact of Secondhand Smoke Exposure on Children with Cystic Fibrosis: A Review. Int J Environ Res Public Health (2016) 0.75
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol (2002) 4.85
Internet-enabled interactive multimedia asthma education program: a randomized trial. Pediatrics (2003) 3.08
Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol (2003) 2.93
Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol (2010) 2.61
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med (2002) 2.50
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med (2003) 2.26
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet (2012) 2.14
Home and allergic characteristics of children with asthma in seven U.S. urban communities and design of an environmental intervention: the Inner-City Asthma Study. Environ Health Perspect (2002) 2.13
Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med (2005) 2.13
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med (2008) 2.05
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med (2011) 2.04
Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol (2011) 2.01
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr (2008) 1.96
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A (2006) 1.95
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 1.91
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest (2003) 1.86
Characterization of a human surfactant protein A1 (SP-A1) gene-specific antibody; SP-A1 content variation among individuals of varying age and pulmonary health. Am J Physiol Lung Cell Mol Physiol (2006) 1.83
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol (2011) 1.81
Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol (2002) 1.80
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther (2006) 1.78
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest (2009) 1.73
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros (2008) 1.71
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.70
Acute respiratory health effects of air pollution on children with asthma in US inner cities. J Allergy Clin Immunol (2008) 1.67
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. Am J Respir Crit Care Med (2014) 1.66
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study. J Pediatr (2005) 1.59
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. Contemp Clin Trials (2009) 1.53
Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol (2005) 1.48
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther (2007) 1.47
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med (2003) 1.45
Primary pulmonary dysgenesis in velocardiofacial syndrome: a second patient. Am J Med Genet A (2003) 1.42
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis. J Clin Microbiol (2003) 1.40
An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol (2010) 1.37
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros (2009) 1.35
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol (2006) 1.34
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis (2013) 1.34
Images in cardiovascular medicine. Right aortic arch with aberrant left innominate artery: a rare vascular ring. Circulation (2009) 1.33
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol (2010) 1.29
Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med (2008) 1.29
Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA (2012) 1.25
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol (2010) 1.24
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol (2007) 1.19
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis (2007) 1.19
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol (2008) 1.13
Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax (2012) 1.12
Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med (2007) 1.11
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol (2011) 1.10
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol (2007) 1.08
Genetic and reproductive knowledge among adolescents and adults with cystic fibrosis. Chest (2008) 1.07
Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys (2012) 1.06
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros (2012) 1.05
Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol (2014) 1.05
Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol (2005) 1.04
Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol (2007) 1.03
Comparative sequencing of the serine-aspartate repeat-encoding region of the clumping factor B gene (clfB) for resolution within clonal groups of Staphylococcus aureus. J Clin Microbiol (2005) 1.02
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros (2013) 1.00
Achieving asthma control in the inner city: do the National Institutes of Health Asthma Guidelines really work? J Allergy Clin Immunol (2010) 0.99
Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience. Brachytherapy (2011) 0.99
Official American Thoracic Society technical standards: flexible airway endoscopy in children. Am J Respir Crit Care Med (2015) 0.98
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother (2005) 0.97
Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. Pediatr Pulmonol (2008) 0.97
Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc (2014) 0.97
Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc (2014) 0.97
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros (2009) 0.96
Physiologic evidence for high-frequency chest wall oscillation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis. Phys Ther (2005) 0.95
Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics (2007) 0.95